drugset / Trial / NCT01314898

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

NCT01314898

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

24-hr urinary sodium/potassium ratio will be a sensitive biomarker of antimineralocorticoid activity. The dose-response relationship of the antimineralocorticoid activity of PF-03882845 can be established following single oral doses.

Timeline

Start
2011-03
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03882845 Small molecule 3 mg Oral
Subject PF-03882845 Small molecule 10 mg Oral
Subject PF-03882845 Small molecule 30 mg Oral
Subject PF-03882845 Small molecule 100 mg Oral
Subject Spironolactone Small molecule 100 mg Oral

Indications

No indication recorded.